Dr. Marie-anne Salvio, PH.D. Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 957 S Lois Ter, Suite 102, Inverness, FL 34452 Phone: 352-341-0200 Fax: 352-341-0700 |
Faith J Powers, PSY.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 111 W Main St Ste 307, Inverness, FL 34450 Phone: 352-201-4955 |
Dr. Susan C Reeder, PH.D. Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 480 Pleasant Grove Rd, Inverness, FL 34452 Phone: 352-344-2320 Fax: 352-344-4849 |
News Archive
Almost one-third of U.S. children take some form of dietary supplement, most often multivitamins and multiminerals, according to a study conducted in part by researchers at RTI International and the Office of Dietary Supplements at the National Institutes of Health.
AYOXXA Biosystems GmbH, an international biotechnology company, will develop a multiplex assay to support the treatment of sepsis patients as part of the project "SepsisData.Net.NRW - Digitized Pattern Recognition for Personalized Treatment of Sepsis Patients". The development will be based on the Company's innovative bead-based protein analysis platform LUNARIS™.
Sudden hearing loss can be experienced in highly stressful situations, usually lasting a short time. Researchers at São Paulo State University in Brazil, collaborating with colleagues at Oxford Brookes University in the United Kingdom, have reported a discovery that contributes to a deeper understanding of this phenomenon.
Inimex Pharmaceuticals and SARomics Biostructures announce that they have achieved a scientific milestone in their collaboration to solve the structure of Inimex's Innate Defense Regulator (IDR) IMX942 in complex with its target, the ZZ domain of human p62 (sequestosome-1). No structures were previously available for this challenging protein domain. The crystal structure determined by SARomics Biostructures provides invaluable information that will assist the functional understanding of IMX942 and the development of the new generation of IDRs.
The company is pleased to announce that after receiving Ethical Committee (EC) and Ministry of Health (MOH) approval, for the first human use of the company's FastSeal Bioabsorbable Vascular Access Closure System, Phase I of the First in Human (FIH) clinical testing has been completed, with 100% successful results, and no adverse effects, including post procedural discomfort.
› Verified 6 days ago